Your browser doesn't support javascript.
loading
Clinical Use of Trabecular Bone Score: The 2023 ISCD Official Positions.
Goel, Heenam; Binkley, Neil; Boggild, Miranda; Chan, Wing P; Leslie, William D; McCloskey, Eugene; Morgan, Sarah L; Silva, Barbara C; Cheung, Angela M.
Afiliação
  • Goel H; CentraCare, Saint Cloud, MN United States. Electronic address: heenam.goel@centracare.com.
  • Binkley N; University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
  • Boggild M; University of Toronto, Department of Medicine, Toronto, Canada.
  • Chan WP; Department of Radiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; and Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Leslie WD; Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.
  • McCloskey E; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK.
  • Morgan SL; University of Alabama at Birmingham, Osteoporosis Prevention and Treatment Clinic and DXA Facility, Birmingham, AL, United States.
  • Silva BC; Medical School, Centro Universitario de Belo Horizonte (UniBH), MG, Brazil Bone Metabolic diseases Unit, Santa Casa Hospital, Belo Horizonte, MG, Brazil Clinic of Endocrinology, Felicio Rocho Hospital, Belo Horizonte, MG, Brazil.
  • Cheung AM; Centre of Excellence in Skeletal Health Assessment, University of Toronto, Toronto, Ontario, Canada; Osteoporosis Program, University Health Network and Sinai Health System, Toronto, Ontario, Canada.
J Clin Densitom ; 27(1): 101452, 2024.
Article em En | MEDLINE | ID: mdl-38228014
ABSTRACT
Osteoporosis can currently be diagnosed by applying the WHO classification to bone mineral density (BMD) assessed by dual-energy x-ray absorptiometry (DXA). However, skeletal factors other than BMD contribute to bone strength and fracture risk. Lumbar spine TBS, a grey-level texture measure which is derived from DXA images has been extensively studied, enhances fracture prediction independent of BMD and can be used to adjust fracture probability from FRAX® to improve risk stratification. The purpose of this International Society for Clinical Densitometry task force was to review the existing evidence and develop recommendations to assist clinicians regarding when and how to perform, report and utilize TBS. Our review concluded that TBS is most likely to alter clinical management in patients aged ≥ 40 years who are close to the pharmacologic intervention threshold by FRAX. The TBS value from L1-L4 vertebral levels, without vertebral exclusions, should be used to calculate adjusted FRAX probabilities. L1-L4 vertebral levels can be used in the presence of degenerative changes and lumbar compression fractures. It is recommended not to report TBS if extreme structural or pathological artifacts are present. Monitoring and reporting TBS change is unlikely to be helpful with the current version of the TBS algorithm. The next version of TBS software will include an adjustment based upon directly measured tissue thickness. This is expected to improve performance and address some of the technical factors that affect the current algorithm which may require modifications to these Official Positions as experience is acquired with this new algorithm.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Fraturas por Osteoporose Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Fraturas por Osteoporose Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article